Morningstar

Slingshot Biosciences Launches TruCytes™ Potency CD20 & CD34 Stem Cell Gating Controls, Standardizing Critical Readouts While Slashing Variability, Time, and Cost

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...
Nasdaq

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle ...

TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology ...
MedPage Today

Stem Cell Selection Unneeded for SSc Transplant Therapy?

Autologous stem cell transplant for patients with diffuse systemic sclerosis (SSc), without selecting for a particular hematopoietic cell type, performed about as well in a new single-arm trial as was ...
Targeted Oncology

Early Immune Intervention is Key to Managing Posttransplant Relapse in AML

Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve outcomes for patients with acute myeloid leukemia (AML) who undergo allogeneic ...

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

(Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating ...